Zacks Investment Research upgraded shares of GenMark Diagnostics (NASDAQ:GNMK) from a sell rating to a hold rating in a research report released on Wednesday.

According to Zacks, “GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx’s eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual’s ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual’s increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. “

GNMK has been the subject of several other reports. BidaskClub lowered shares of GenMark Diagnostics from a buy rating to a hold rating in a research note on Thursday, October 4th. ValuEngine raised shares of GenMark Diagnostics from a sell rating to a hold rating in a research note on Friday, November 2nd. Finally, Canaccord Genuity dropped their price objective on shares of GenMark Diagnostics from $10.00 to $9.00 and set a buy rating for the company in a research note on Tuesday, October 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $10.33.

NASDAQ GNMK opened at $5.13 on Wednesday. The company has a quick ratio of 3.10, a current ratio of 3.75 and a debt-to-equity ratio of 0.69. The firm has a market cap of $287.05 million, a price-to-earnings ratio of -4.24 and a beta of 1.27. GenMark Diagnostics has a 52 week low of $3.98 and a 52 week high of $8.81.

GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings data on Monday, October 29th. The medical equipment provider reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). The company had revenue of $15.80 million during the quarter, compared to analyst estimates of $15.76 million. GenMark Diagnostics had a negative net margin of 79.33% and a negative return on equity of 95.36%. Analysts predict that GenMark Diagnostics will post -0.86 EPS for the current fiscal year.

In other news, insider Hany Massarany sold 8,047 shares of the business’s stock in a transaction on Tuesday, November 20th. The shares were sold at an average price of $4.84, for a total transaction of $38,947.48. Following the completion of the sale, the insider now directly owns 672,883 shares of the company’s stock, valued at $3,256,753.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 21,250 shares of company stock valued at $104,722 over the last three months. Insiders own 7.50% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of GNMK. Commonwealth Equity Services LLC purchased a new stake in shares of GenMark Diagnostics during the second quarter valued at $115,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of GenMark Diagnostics during the second quarter valued at $152,000. Virtu Financial LLC purchased a new stake in shares of GenMark Diagnostics during the third quarter valued at $179,000. Engineers Gate Manager LP purchased a new stake in shares of GenMark Diagnostics during the third quarter valued at $213,000. Finally, MetLife Investment Advisors LLC boosted its stake in shares of GenMark Diagnostics by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 40,896 shares of the medical equipment provider’s stock valued at $301,000 after purchasing an additional 14,546 shares during the period. 97.02% of the stock is owned by hedge funds and other institutional investors.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Further Reading: How to Invest in the Dividend Aristocrat Index

Get a free copy of the Zacks research report on GenMark Diagnostics (GNMK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.